Managing painful neuropathy in diabetes

Polskie Archiwum Medycyny Wewnetrznej

Volumn 118, Issue 5, 2008, Pages 260-261

  Jude, Edward B ^a   Jacob, Koshy ^a  

^a TAMESIDE GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; CAPSAICIN; CARBAMAZEPINE; CITALOPRAM; DESIPRAMINE; DEXTROMETHORPHAN; DULOXETINE; GABAPENTIN; IMIPRAMINE; ISOSORBIDE DINITRATE; LAMOTRIGINE; MEXILETINE; NONSTEROID ANTIINFLAMMATORY AGENT; OXCARBAZEPINE; OXYCODONE; PARACETAMOL; PLACEBO; PREGABALIN; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID;

ABSENCE OF SIDE EFFECTS; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC NEUROPATHY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EDITORIAL; HUMAN; MORBIDITY; PAIN; PAIN ASSESSMENT; PREVALENCE; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; TREATMENT OUTCOME;

DIABETIC NEUROPATHIES; HUMANS;

EID: 45249098499     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.378     Document Type: Editorial

References (13)

1. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004; 27: 1047-1053.
2. Daousi C, MacFarlane IA, Woodward A, et al. Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes. Diabet Med. 2004; 21: 976-982.
3. Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care. 2006; 29: 1518-1522.
4. Jude E, Boulton AJM. End stage complications of diabetic neuropathy. Diabetes Rev. 1999; 7: 395-410.
5. Vileikyte L, Rubin RR, Leventhal H. Psychological aspects of diabetic neuropathic foot complications: an overview. Misconceptions, assessment of patient beliefs and behaviour, illness perception at the individual level. Diabetes Metab Res Rev. 2004; 20: S13-S18.
6. Gore M, Brandenburg NA, Hoffman DL, et al. Burden of illness in painful diabetic peripheral neuropathy: the patients' perspectives. J Pain. 2006; 7: 892-900.
7. Benbow SJ, Wallymahmed ME, MacFarlane IA. Diabetic peripheral neuropathy and quality of life. QJM. 1998; 91: 733-737.
8. Boulton AJM, Drury J, Clarke, Ward JD. Continous subcutaneous insulin infusion in the management of painful diabetic neuropathy. Diabetes Care. 1982; 5: 386-390.
9. Oyibo S, Prasad YD, Jackson NJ, et al. The relationship between blood glucose excursions and painful diabetic peripheral neuropathy. Diabet Med. 2002; 19: 870-873.
10. Jensen TS, Backonja MM, Hernández Jiménez S, et al. New perspectives on the management of diabetic peripheral neuropathic pain. Diabetes Vasc Dis Res. 2006; 3: 108-119.
11. Toelle T, Xu X, Sadosky AB. Painful diabetic neuropathy: a cross-sectional survey of health state impairment and treatment patterns. J Diabetes Complicat. 2006; 20: 26-33.
12. Wong M, Chung JWY, Wong TKS. Effects of treatments for symptoms of painful diabetic neuropathy: systematic review. BMJ. 2007; 335: 87-90.
13. McCarberg B, Billington R. Consequences of neuropathic pain: quality of life issues and associated costs. Am J Manag Care. 2006; 12: S263-S268.